At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 57 enrolled
Drug / intervention
Avacopan +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double Blind, Placebo Controlled Phase 2 Study to Evaluate the Safety and Efficacy of Avacopan (CCX168) in Patients With C3 Glomerulopathy
In Brief
A Phase 2 clinical trial evaluating Avacopan and Avacopan Matching Placebo for C3 Glomerulopathy (C3G). Completed, enrolled 57 participants across 45 sites in 11 countries.
Detailed Summary
The aim of this trial is to evaluate the effect of avacopan treatment on renal disease activity in patients with complement component 3 glomerulopathy (C3G). Funding Source - FDA OOPD
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsC3 Glomerulopathy (C3G)
CountriesBelgium, Canada, Denmark, France, Germany, Ireland, Italy, Netherlands, Spain, United Kingdom, United States
CollaboratorsMedpace, Inc.
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
Enrollment StartSep 2017
First PostedOct 2017
Primary CompletionMar 2021
Study CompletionOct 2021
TodayJul 2026
First PostedOct 4, 2017
Enrollment StartSep 29, 2017
Primary CompletionMar 3, 2021
Study CompletionOct 27, 2021
TodayJul 2, 2026
Enrollment to primary: 3.4 yearsPosted 8.7 years ago
Interventions
Avacopandrug
Orally administered
Avacopan Matching Placebodrug
avacopan matching placebo